GlassScriptPhysician profile
Jonathan J Fillmore
NPI 1578592713
$11,906.82
in general payments reported to CMS, 2019-2025
48 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,636 · 2020: $733 · 2021: $679 · 2022: $1,224 · 2023: $2,997 · 2024: $2,577 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,591 · Education: $43.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,591.35 |
| Education | $43.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,311.16 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,390.76 | 2019-2025 | Jardiance, Mounjaro, Humulin |
| Xeris Pharmaceuticals, INC. | $877.39 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Valeritas, INC. | $758.22 | 2019 | |
| Abbott Laboratories | $677.73 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $535.37 | 2022-2025 | Jardiance |
| Amgen INC. | $495.44 | 2019-2025 | Evenity, Prolia, Tepezza |
| Corcept Therapeutics | $404.68 | 2019-2025 | Korlym |
| Abbvie INC. | $349.79 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $315.82 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $240.61 | 2022-2024 | |
| Antares Pharma, INC. | $222.37 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Medtronic Minimed, INC. | $197.04 | 2019-2020 | |
| Insulet Corporation | $165.12 | 2019-2024 | Omnipod |
| Ascensia Diabetes Care US INC. | $142.11 | 2023-2024 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Fillmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.